NCT00150592View on ClinicalTrials.gov

Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17

PHASE2CompletedINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

May 12, 2005

Primary Completion Date

October 5, 2005

Study Completion Date

October 5, 2005

Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
DRUG

SPD503 (Guanfacine HCl)

DRUG

Placebo

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY